
Perioperative Durvalumab-Based Regimen Receives European Approval for Resectable NSCLC
The European Commission has granted approval to durvalumab (Imfinzi) for use as neoadjuvant therapy in combination with chemotherapy and as adjuvant monotherapy for the treatment of patients with resectable non–small cell lung cancer (NSCLC) at high risk …